---
title: "HCW Biologics Inc. Q2 2026: Revenue $135.6K, EPS $(11.58) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295968025.md"
description: "HCW Biologics Inc. reported Q2 2026 revenue of $135.6K and a net loss of $(15.37M). Diluted EPS narrowed to $(11.58) from $(40.72) YoY. The company recognized $6.7M in H1 2026 from the Trimmune license. Clinically, HCW9302 showed positive Phase 1 results for alopecia areata. HCW Biologics is repositioning HCW9201/9206 as manufacturing reagents and preparing IND studies for HCW11-018b, aiming for Phase 1 in H1 2027."
datetime: "2026-08-14T19:41:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295968025.md)
  - [en](https://longbridge.com/en/news/295968025.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295968025.md)
generator: "portal-rs"
---

# HCW Biologics Inc. Q2 2026: Revenue $135.6K, EPS $(11.58) — 10-Q Summary

HCW Biologics Inc. reported second-quarter 2026 results with revenue of $135.6K and a net loss attributable to common stockholders of $(15.37M); diluted loss per share narrowed to $(11.58) versus $(40.72) a year earlier.

**Financial Highlights**

-   Revenue: $135.6K for Q2 2026, versus $6.6K in the year-ago quarter (increase of $129.0K YoY).
-   Net income: Net loss attributable to common stockholders of $(15.37M) for Q2 2026, versus net loss of $(12.08M) in the year-ago quarter (worse YoY).
-   Diluted EPS: $(11.58) for Q2 2026, versus $(40.72) in the year-ago quarter (loss narrowed YoY).

**Business Highlights**

-   Revenue growth and licensing: Recognized $6.7M in H1 2026 from the Trimmune license, including a $3.5M upfront payment and deferred services revenue.
-   Clinical momentum: Reported a positive preliminary Phase 1 readout for HCW9302 in alopecia areata with no dose-limiting toxicities; a full readout is expected by Q4 2026.
-   Product and commercial shift: Reclaimed rights to HCW9201/9206 and is repositioning them as manufacturing reagents for cell‑based therapies targeting commercialization opportunities.
-   Pipeline advancement: Preparing IND-enabling studies and planning a Type B pre‑IND engagement for HCW11-018b, a T‑cell engager, with a Phase 1 start aimed for H1 2027.
-   Operational restructuring and partnerships: Settled key vendor liabilities and is pursuing commercialization partnerships for reagents alongside CDMO GMP manufacturing plans.

Original SEC Filing: HCW Biologics Inc. \[ HCWB \] - 10-Q - Aug. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [HCWB.US](https://longbridge.com/en/quote/HCWB.US.md)

## Related News & Research

- [HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results | HCWB Stock News](https://longbridge.com/en/news/295966778.md)
- [HCWB: Positive clinical data, higher licensing revenue, and new equity funding offset by net loss and funding risks](https://longbridge.com/en/news/295967027.md)
- [Public Storage announces R$ 0.41 per unit dividend for Q3 2026](https://longbridge.com/en/news/296635332.md)
- [Corning sets Q3 2026 dividend at R$ 0.25 per unit](https://longbridge.com/en/news/296635714.md)
- [Northrop Grumman announces R$ 0.17 per unit dividend for Q3 2026](https://longbridge.com/en/news/296645808.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**